Quantcast
Last updated on April 18, 2014 at 14:49 EDT

Latest Panitumumab Stories

2008-06-30 12:03:15

Takeda Pharmaceutical and Takeda Bio Development Center have submitted a new drug application of anti-cancer agent, panitumumab for the treatment of patients with progressed or relapse colorectal cancer to the Ministry of Health Labour and Welfare in Japan. Panitumumab is a fully-human monoclonal antibody which binds to epidermal growth factor receptor and suppresses tumor growth. It shows a low incidence of allergic reaction upon and also after administration as it is a fully-human...

2008-06-26 18:02:59

Amgen (NASDAQ: AMGN) today announced updated results from the "STEPP" (Skin Toxicity Evaluation Protocol with Panitumumab) trial, the first prospective study to examine differences between preemptive and reactive skin treatment for skin toxicities in metastatic colorectal cancer (mCRC) patients receiving epidermal growth factor receptor (EGFr) therapy. The analysis found that preemptive treatment reduced the incidence rate of grade 2 and greater skin toxicities by over 50 percent without...

2008-06-24 09:03:24

IRVING, Texas and PHOENIX, June 24 /PRNewswire/ -- Caris Diagnostics (Caris Dx), a leading provider of the highest quality diagnostic, translational development and pharmaceutical services encompassing anatomic pathology and molecular testing, announced that it is now offering KRAS mutation analysis, designed to provide information on which colon cancer patients are most likely to respond to cetuximab (Erbitux) co-marketed by ImClone and Bristol-Myers Squibb or panitumumab (Vectibix)...

2008-06-20 12:00:46

Merck KGaA has submitted an application to the European Medicines Agency to broaden the use of the targeted therapy Erbitux to include first-line treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck. The submitted label would extend the use of Erbitux for treatment of patients with recurrent or metastatic squamous cell cancer of the head and neck in combination with platinum-based chemotherapy. The submission is supported by data from the...

2006-06-12 15:51:28

LOS ANGELES (Reuters) - Biotechnology company Amgen Inc. said on Monday that the U.S. Food and Drug Administration has agreed to a "priority review" of the company's application for experimental drug panitumumab as a treatment for colon cancer. With priority review status, the FDA will make its decision on whether to approve the drug within six months, rather than the usual 10- to 12-month review period. The agency grants priority review to products that are considered to be...

2006-06-05 07:40:00

By Toni Clarke ATLANTA (Reuters) - Using combinations of "smart bomb" cancer drugs that target specific proteins and avoid the indiscriminate cell destruction of chemotherapy may be the wave of the future for cancer patients, experts say. Early studies show that combining targeted treatments such as Genentech Inc.'s breast cancer drug Herceptin with GlaxoSmithKline Plc's experimental treatment Tykerb, may be helpful in patients who do not respond to Herceptin alone, said Dr. Jose Baselga,...

2006-06-04 13:45:17

LOS ANGELES (Reuters) - Amgen Inc. said on Saturday that testing tumors for the protein that its experimental colon cancer drug panitumumab is designed to target is not an accurate measure of whether a patient will respond to the treatment. Two clinical trials funded by Amgen show that some patients who tested negative for epidermal growth factor receptor, the protein on the surface of cancer cells that the drug is designed to block, responded to the treatment, while others who...

2006-06-03 15:11:46

By Toni Clarke ATLANTA (Reuters) - Using combinations of "smart bomb" cancer drugs that target specific proteins and avoid the indiscriminate cell destruction of chemotherapy may be the wave of the future for cancer patients, experts say. Early studies show that combining targeted treatments such as Genentech Inc.'s breast cancer drug Herceptin with GlaxoSmithKline Plc's experimental treatment Tykerb, may be helpful in patients who do not respond to Herceptin alone, said Dr. Jose...

2006-04-03 13:25:12

By Megan Rauscher WASHINGTON (Reuters Health) - Among patients with colorectal cancer that has spread to other areas of the body and who have not been helped by standard chemotherapy, a new drug called panitumumab produces a highly significant improvement in time without worsening of disease, according to data released at the annual meeting of the American Association for Cancer Research. "Panitumumab is a new important treatment option for patients with chemo-resistant colorectal...

2005-11-03 14:13:13

CHICAGO (Reuters) - Amgen Inc. and Abgenix Inc. said on Thursday a late-stage study found its experimental drug panitumumab helped slow tumor progression in patients with advanced colon cancer who had failed multiple other therapies. In the 463-patient trial, patients who received panitumumab every two weeks showed a 46 percent decrease in tumor progression rate versus those who received best supportive care alone, the companies said. The result was better than the pre-set goal of a...